Collaborative Drug Discovery

PureTech established the underlying programs and platforms that have resulted in a substantial pipeline comprised of 24 product candidates and one product cleared by the FDA that are being advanced internally or by its affiliates. View our corporate deck.

View our pipeline at a glance or scroll down for more details on individual programs

Internal R&D Programs

PureTech's internal programs are focused on harnessing the lymphatic system and related immunology mechanisms for the treatment of cancer, immunological, lymphatic and CNS-related disorders. The lymphatic system serves as a "superhighway" for immune cell trafficking, connects all tissues to regional lymph nodes and is essential for fluid balance.

Affiliate programs

The affiliates include 13 clinical-stage product candidates, including one product that has been cleared by the FDA and a second product candidate that has been filed with the FDA for review, and several other novel preclinical programs that have been developed in collaboration with some of the world's leading scientific experts.

Highlighted Programs

Note: Ordered below by PureTech ownership; lines represent the most advanced stage of each product candidate; not comprehensive of preclinical and discovery programs.

BIG - Brain Immune Gut
TRIAL PHASE
Product Candidate**
PureTech Ownership†
Initial Indications
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
100% (Internal)
Lymphedema

Initial Indication(s):

Lymphedema

Patient Population:

~1 million

Collaborators and Partners:

teva  memorialSloanKet

Key Differentiation:

Product candidate for lymphedema with encouraging in-human pharmacokenetics

LYT-200
100% (Internal)
Solid Tumors

Initial Indication(s):

Solid tumors, including colorectal, pancreatic, cholangiocarcinoma

Patient Population:

~57K (Pancreatic cancer)
~146K (CRC)
~8K (Cholangiocarcinoma)

Collaborators and Partners:

NYU

Key Differentiation:

Capacity to concurrently modulate multiple immunosuppressive pathways and deliver significant single agent activity

LYT-210
100% (Internal)
Solid Tumors, Autoimmune Disorders

Initial Indication(s):

Solid Tumors
Autoimmune Disorders

Collaborators and Partners:

NYU

Key Differentiation:

Focused on a therapeutic strategy which is distinct from other interventions using or targeting cytotoxic γδ T cells

ALV-306
82.7% (Alivio)
Distal Colitis, Pouchitis

Initial Indication(s):

Distal Colitis
Pouchitis

Patient Population:

~225K (Distal Colitis)
70 – 135K (Pouchitis)

Collaborators and Partners:

harvardMITBWH

Key Differentiation:

Novel technology that selectively binds to inflamed tissues and allows for targeted chronic and acute inflammatory disorders

ALV-304
82.7% (Alivio)
IBD

Initial Indication(s):

IBD

Patient Population:

~3M

Collaborators and Partners:

harvardMITBWH

Key Differentiation:

Novel technology that selectively binds to inflamed tissues and allows for targeted treatment of chronic and acute inflammatory disorders

ALV-107
82.7% (Alivio)
IC/BPS

Initial Indication(s):

IC/BPS

Patient Population:

4-12M

Collaborators and Partners:

harvardMITBWHpurdue

Key Differentiation:

Novel technology that selectively binds to inflamed tissues and allows for targeted treatment of chronic and acute inflammatory disorders

FOL-004
77.9% (Follica) R
Androgenetic Alopecia

Initial Indication(s):

Androgenetic alopecia

Patient Population:

~65M

Collaborators and Partners:

Penn

Key Differentiation:

Pioneering technology focused on the creation of new hair follicles via skin disruption and subsequent treatment to enhance effect

FOL-005
77.9% (Follica) R
Skin Rejuvenation

Initial Indication(s):

Skin rejuvenation

Patient Population:

~3.9M

Collaborators and Partners:

Penn

Key Differentiation:

Pioneering technology focused on the creation of new hair follicles via skin disruption and subsequent treatment to enhance effect

ENT-100
72.9% (Entrega)
Metabolic Disorders

Initial Indication(s):

Metabolic disorders

Collaborators and Partners:

MIT  Lilly

Key Differentiation:

Designed to enable oral delivery of biologics, vaccines, and forms of medication that are not efficient in reaching the bloodstream when taken orally

VE303
53.3% (Vedanta)
rCDI

Initial Indication(s):

rCDI

Patient Population:

100-120K per year

Collaborators and Partners:

keioU

Key Differentiation:

Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

VE202
53.3% (Vedanta)
IBD

Initial Indication(s):

IBD

Patient Population:

~3M

Collaborators and Partners:

keioUjanssen

Key Differentiation:

Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

VE416
53.3% (Vedanta)
Food Allergy

Initial Indication(s):

Food allergy

Patient Population:

~2.5M

Collaborators and Partners:

keioU

Key Differentiation:

Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

VE800
53.3% (Vedanta)
Solid Tumors

Initial Indication(s):

Solid tumors
including MSS CRC,
gastric, and melanoma

Patient Population:

~46K (MSS CRC)
~11K (Gastric)
~9K (Melanoma)

Collaborators and Partners:

keioUbristol meyers

Key Differentiation:

Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

Sonde*
55.9% (Sonde)
Depression Detection

Initial Indication(s):

Depression detection

Patient Population:

~17M

Collaborators and Partners:

UNSWBlackDogUmassMedCenterYalePartners

Key Differentiation:

Being developed to enable consumer devices to provide effective disease screening and management solutions based on analysis of voice capture to address a range of health care needs from depression to respiratory to cardiovascular and aging-related conditions

KarXT
31.6% (Karuna) R
Schizophrenia, AD Psychosis, Pain

Initial Indication(s):

Schizophrenia, psychosis in Alzheimer's, pain

Patient Population:

~2.7M (Schizophrenia)
~5.7M (with Alzheimer's; ~50% develop psychosis)

Collaborators and Partners:

Lilly

AKL-T01*
34.9% (Akili)
Pediatric ADHD

Initial Indication(s):

Pediatric ADHD

Patient Population:

~6.4M

Collaborators and Partners:

UCSFshionogi

Key Differentiation:

Pioneering the development of treatments with direct therapeutic activity, delivered through a high-quality action video game experience

AKL-T02*
34.9% (Akili)
Autism

Initial Indication(s):

Autism

Patient Population:

~1.5M

Collaborators and Partners:

UCSFshionogi

Key Differentiation:

Pioneering the development of treatments with direct therapeutic activity, delivered through a high-quality action video game experience

AKL-T03*
34.9% (Akili)
MDD, MS

Initial Indication(s):

Major Depressive Disorder (MDD)
Multiple Sclerosis (MS)

Patient Population:

~17M (MDD)
~900K (MS)

Collaborators and Partners:

UCSFshionogi

Key Differentiation:

Pioneering the development of treatments with direct therapeutic activity, delivered through a high-quality action video game experience

AKL-T04*
34.9% (Akili)
MDD

Initial Indication(s):

Major Depressive Disorder (MDD)

Patient Population:

~17M

Collaborators and Partners:

UCSFshionogi

Key Differentiation:

Pioneering the development of treatments with direct therapeutic activity, delivered through a high-quality action video game experience

VOR33
30.2% (Vor)
AML

Initial Indication(s):

Acute Myeloid Leukemia (AML)

Patient Population:

~60K

Collaborators and Partners:

novartisOUP

Key Differentiation:

Advancing a new approach to selectively protect healthy normal cells from targeted therapies being used to treat hematologic malignancies 

RTB101
27.4% (resTORbio)
Respiratory Illness, Parkinson’s

Initial Indication(s):

Clinically symptomatic
respiratory illness,
Parkinson's disease

Patient Population:

~40M (Clinically
symptomatic respiratory
illness)
~680K (Parkinson's disease)

Collaborators and Partners:

novartis

Key Differentiation:

Developing innovative medicines that target biology of aging to prevent/treat aging-related disorders

PLENITY*
19.5% (Gelesis) R
Overweight and Obesity
FDA Cleared

Initial Indication(s):

Overweight and obese

Patient Population:

~160M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Only prescription weight management product to be cleared for use by overweight adults with a BMI as low was 25 kg/m2, with and without comorbidities such as hypertension, type 2 diabetes, or dyslipidemia

GS500*
19.5% (Gelesis) R
CIC

Initial Indication(s):

Chronic idiopathic constipation (CIC)

Patient Population:

~35M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Designed an approach for weight loss with an oral, non-invasive, non-systemic mechanism of action

Gelesis200*
19.5% (Gelesis) R
Weight Management in T2D/Prediabetes

Initial Indication(s):

Weight management in T2D and pre-diabetes

Patient Population:

~84M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Designed an approach for weight loss with an oral, non-invasive, non-systemic mechanism of action

GS300*
19.5% (Gelesis) R
NASH/NAFLD

Initial Indication(s):

NASH/NAFLD

Patient Population:

80-100M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Designed an approach for weight loss with an oral, non-invasive, non-systemic mechanism of action

GS400*
19.5% (Gelesis) R
IBD

Initial Indication(s):

IBD

Patient Population:

~3M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Designed an approach for weight loss with an oral, non-invasive, non-systemic mechanism of action

BIG - Brain Immune Gut
LYT-100
Lymphedema
100% (Internal)
1

Initial Indication(s):

Lymphedema

Patient Population:

~1 million

Collaborators and Partners:

teva  memorialSloanKet

Key Differentiation:

Product candidate for lymphedema with encouraging in-human pharmacokenetics

LYT-200
Solid Tumors
100% (Internal)
Preclinical

Initial Indication(s):

Solid tumors, including colorectal, pancreatic, cholangiocarcinoma

Patient Population:

~57K (Pancreatic cancer)
~146K (CRC)
~8K (Cholangiocarcinoma)

Collaborators and Partners:

NYU

Key Differentiation:

Capacity to concurrently modulate multiple immunosuppressive pathways and deliver significant single agent activity

LYT-210
Solid Tumors, Autoimmune Disorders
100% (Internal)
Preclinical

Initial Indication(s):

Solid Tumors
Autoimmune Disorders

Collaborators and Partners:

NYU

Key Differentiation:

Focused on a therapeutic strategy which is distinct from other interventions using or targeting cytotoxic γδ T cells

ALV-306
Distal Colitis, Pouchitis
82.7% (Alivio)
Preclinical

Initial Indication(s):

Distal Colitis
Pouchitis

Patient Population:

~225K (Distal Colitis)
70 – 135K (Pouchitis)

Collaborators and Partners:

harvardMITBWH

Key Differentiation:

Novel technology that selectively binds to inflamed tissues and allows for targeted chronic and acute inflammatory disorders

ALV-304
IBD
82.7% (Alivio)
Preclinical

Initial Indication(s):

IBD

Patient Population:

~3M

Collaborators and Partners:

harvardMITBWH

Key Differentiation:

Novel technology that selectively binds to inflamed tissues and allows for targeted treatment of chronic and acute inflammatory disorders

ALV-107
IC/BPS
82.7% (Alivio)
Preclinical

Initial Indication(s):

IC/BPS

Patient Population:

4-12M

Collaborators and Partners:

harvardMITBWHpurdue

Key Differentiation:

Novel technology that selectively binds to inflamed tissues and allows for targeted treatment of chronic and acute inflammatory disorders

FOL-004
Androgenetic Alopecia
77.9% (Follica) R
2

Initial Indication(s):

Androgenetic alopecia

Patient Population:

~65M

Collaborators and Partners:

Penn

Key Differentiation:

Pioneering technology focused on the creation of new hair follicles via skin disruption and subsequent treatment to enhance effect

FOL-005
Skin Rejuvenation
77.9% (Follica) R
2

Initial Indication(s):

Skin rejuvenation

Patient Population:

~3.9M

Collaborators and Partners:

Penn

Key Differentiation:

Pioneering technology focused on the creation of new hair follicles via skin disruption and subsequent treatment to enhance effect

ENT-100
Metabolic Disorders
72.9% (Entrega)
Preclinical

Initial Indication(s):

Metabolic disorders

Collaborators and Partners:

MIT  Lilly

Key Differentiation:

Designed to enable oral delivery of biologics, vaccines, and forms of medication that are not efficient in reaching the bloodstream when taken orally

VE303
rCDI
53.3% (Vedanta)
2

Initial Indication(s):

rCDI

Patient Population:

100-120K per year

Collaborators and Partners:

keioU

Key Differentiation:

Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

VE202
IBD
53.3% (Vedanta)
1

Initial Indication(s):

IBD

Patient Population:

~3M

Collaborators and Partners:

keioUjanssen

Key Differentiation:

Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

VE416
Food Allergy
53.3% (Vedanta)
1

Initial Indication(s):

Food allergy

Patient Population:

~2.5M

Collaborators and Partners:

keioU

Key Differentiation:

Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

VE800
Solid Tumors
53.3% (Vedanta)
Preclinical

Initial Indication(s):

Solid tumors
including MSS CRC,
gastric, and melanoma

Patient Population:

~46K (MSS CRC)
~11K (Gastric)
~9K (Melanoma)

Collaborators and Partners:

keioUbristol meyers

Key Differentiation:

Developing a new category for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria

Sonde*
Depression Detection
55.9% (Sonde)
1

Initial Indication(s):

Depression detection

Patient Population:

~17M

Collaborators and Partners:

UNSWBlackDogUmassMedCenterYalePartners

Key Differentiation:

Being developed to enable consumer devices to provide effective disease screening and management solutions based on analysis of voice capture to address a range of health care needs from depression to respiratory to cardiovascular and aging-related conditions

KarXT
Schizophrenia, AD Psychosis, Pain
31.6% (Karuna) R
2

Initial Indication(s):

Schizophrenia, psychosis in Alzheimer's, pain

Patient Population:

~2.7M (Schizophrenia)
~5.7M (with Alzheimer's; ~50% develop psychosis)

Collaborators and Partners:

Lilly

AKL-T01*
Pediatric ADHD
34.9% (Akili)
3

Initial Indication(s):

Pediatric ADHD

Patient Population:

~6.4M

Collaborators and Partners:

UCSFshionogi

Key Differentiation:

Pioneering the development of treatments with direct therapeutic activity, delivered through a high-quality action video game experience

AKL-T02*
Autism
34.9% (Akili)
2

Initial Indication(s):

Autism

Patient Population:

~1.5M

Collaborators and Partners:

UCSFshionogi

Key Differentiation:

Pioneering the development of treatments with direct therapeutic activity, delivered through a high-quality action video game experience

AKL-T03*
MDD, MS
34.9% (Akili)
2

Initial Indication(s):

Major Depressive Disorder (MDD)
Multiple Sclerosis (MS)

Patient Population:

~17M (MDD)
~900K (MS)

Collaborators and Partners:

UCSFshionogi

Key Differentiation:

Pioneering the development of treatments with direct therapeutic activity, delivered through a high-quality action video game experience

AKL-T04*
MDD
34.9% (Akili)
Preclinical

Initial Indication(s):

Major Depressive Disorder (MDD)

Patient Population:

~17M

Collaborators and Partners:

UCSFshionogi

Key Differentiation:

Pioneering the development of treatments with direct therapeutic activity, delivered through a high-quality action video game experience

VOR33
AML
30.2% (Vor)
Preclinical

Initial Indication(s):

Acute Myeloid Leukemia (AML)

Patient Population:

~60K

Collaborators and Partners:

novartisOUP

Key Differentiation:

Advancing a new approach to selectively protect healthy normal cells from targeted therapies being used to treat hematologic malignancies 

RTB101
Respiratory Illness, Parkinson’s
27.4% (resTORbio)
3

Initial Indication(s):

Clinically symptomatic
respiratory illness,
Parkinson's disease

Patient Population:

~40M (Clinically
symptomatic respiratory
illness)
~680K (Parkinson's disease)

Collaborators and Partners:

novartis

Key Differentiation:

Developing innovative medicines that target biology of aging to prevent/treat aging-related disorders

PLENITY*
Overweight and Obesity
19.5% (Gelesis) R
FDA Cleared

Initial Indication(s):

Overweight and obese

Patient Population:

~160M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Only prescription weight management product to be cleared for use by overweight adults with a BMI as low was 25 kg/m2, with and without comorbidities such as hypertension, type 2 diabetes, or dyslipidemia

GS500*
CIC
19.5% (Gelesis) R
2

Initial Indication(s):

Chronic idiopathic constipation (CIC)

Patient Population:

~35M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Designed an approach for weight loss with an oral, non-invasive, non-systemic mechanism of action

Gelesis200*
Weight Management in T2D/Prediabetes
19.5% (Gelesis) R
2

Initial Indication(s):

Weight management in T2D and pre-diabetes

Patient Population:

~84M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Designed an approach for weight loss with an oral, non-invasive, non-systemic mechanism of action

GS300*
NASH/NAFLD
19.5% (Gelesis) R
Preclinical

Initial Indication(s):

NASH/NAFLD

Patient Population:

80-100M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Designed an approach for weight loss with an oral, non-invasive, non-systemic mechanism of action

GS400*
IBD
19.5% (Gelesis) R
Preclinical

Initial Indication(s):

IBD

Patient Population:

~3M

Collaborators and Partners:

UdelSalento

Key Differentiation:

Designed an approach for weight loss with an oral, non-invasive, non-systemic mechanism of action

Note: Lines represent the most advanced stage of each product candidate; not comprehensive of preclinical programs.

†Relevant ownership interests for affiliate programs were calculated on a diluted basis as of 30 June 2019 (other than Follica which is as of 19 July 2019) including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Vor ownership assumes all future tranches are funded in the Series A financing round with PureTech investing an additional $0.7 million, and Sonde ownership assumes all future tranches are funded in the Series A financing round. resTORbio and Karuna ownerships are shown on an outstanding share basis, with resTORbio calculated as of 30 June 2019 and Karuna calculated as of 3 July 2019. With respect to internal programs, PureTech owns 100% of LYT-100, and PureTech owns 100% of LYT-200 and LYT-210 subject to certain interests held by the inventors and advisors to those programs.

R PureTech Health has a right to royalty payments as a percentage of net sales

* These product candidates are regulated as devices and their development has been approximately equated to phases of clinical development

**PureTech is not responsible for development of all of these products. For example: Certain of our Affiliates, including Akili, Karuna, Vor, resTORbio, and Gelesis have independent development teams, and PureTech does not control the development of these Affiliates' product candidates.

The BIG Idea - Moving Medicine Forward at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & capital-efficient prioritization & validation
Develop internally, partner or spin-out

Collaborating with Industry Pioneers Across Our Pipeline of Affiliates and Internal R&D programs

Amgen Novartis Lilly Merck Boehringer Ingelheim Bristol-Myers Squibb Janssen Roche

DISCOVERY REINVENTED

  • Aging Related Immune Disorders
  • Gut/Immune Ecosystem
  • Severe and Chronic Mental Health